Search Result

Results for "

ALK5 kinase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Anaplastic lymphoma kinase (ALK) (11) Apoptosis (2) IKK (1) Isotope-Labeled Compounds (1) Ligands for Target Protein for PROTAC (1) Organoid (6) p38 MAPK (1) PROTACs (1) Reference Standards (3) Src (1) TGF-beta/Smad (4) TGF-β Receptor (25)
By Research Areas:	Cancer (23) Cardiovascular Disease (2) Endocrinology (1) Inflammation/Immunology (8) Metabolic Disease (5) Neurological Disease (1)

Inhibitors & Agonists

Isotope-Labeled Compounds

Targets Recommended: Anaplastic lymphoma kinase (ALK)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10431

SB-431542 Maximum Cited Publications 294 Publications Verification	Organoid TGF-β Receptor Apoptosis	Cancer
SB-431542 is a *TGF-β receptor kinase* inhibitor (TRKI)*. SB-431542 has inhibitory activity for ALK4, ALK5* and ALK7 with IC₅₀ values of 1 μM, 0.75 μM and 2 μM, respectively. SB-431542 also inhibits TGF-β-induced transcription, gene expression, apoptosis, and growth suppression. SB-431542 can be used for the research of cancer and signal transduction pathways .

HY-10432

A 83-01 125+ Cited Publications	Organoid TGF-β Receptor	Cancer
A 83-01 is a potent inhibitor of TGF-β type I receptor **ALK5 kinase, type I nodal receptor ALK4 and type I nodal receptor ALK7, with IC₅₀s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7**, respectively .

HY-13012

RepSox 20+ Cited Publications E-616452; SJN 2511	Organoid TGF-β Receptor	Metabolic Disease
RepSox (E-616452) is a potent and selective transforming growth factor-beta receptor I/activin like kinase 5 (TGF-β-RI/ALK5) inhibitor. RepSox inhibits ALK5 autophosphorylation with an IC₅₀ value of 4 nM. RepSox can be used for the research of obesity and associated metabolic diseases such as type 2 diabetes .

HY-19928

Vactosertib 5+ Cited Publications EW-7197; TEW-7197	TGF-β Receptor	Cancer
Vactosertib (EW-7197) is a potent, orally active and ATP-competitive activin receptor-like kinase 5 (ALK5) inhibitor with an IC₅₀ of 12.9 nM. Vactosertib also inhibits ALK2 and ALK4 (IC₅₀ of 17.3 nM) at nanomolar concentrations. Vactosertib has potently antimetastatic activity and anticancer effect .

HY-10432A

A 83-01 sodium 125+ Cited Publications	Organoid TGF-β Receptor	Cancer
A 83-01 sodium is a potent inhibitor of TGF-β type I receptor ALK5 kinase, *ALK4* and *ALK7, with IC₅₀s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4* and *ALK7*, respectively .

HY-16712

LDN-214117 2 Publications Verification	TGF-β Receptor	Cancer
LDN-214117 is an orally active ALK2 inhibitor with well-tolerated and good brain penetration. LDN-214117 has a high selectivity and low cytotoxicity for ALK2 with an IC₅₀ value of 24 nM. LDN-214117 also is a specific bone morphogenetic proteins (BMPs) signaling inhibitor and has relatively selective inhibition for BMP6 with an IC₅₀ value of 100 nM. LDN-214117 can be used for the research of fibrodysplasia ossificans progressiva (FOP), diffuse intrinsic pontine glioma (DIPG) .

HY-19928A

Vactosertib Hydrochloride 5+ Cited Publications EW-7197 Hydrochloride; TEW-7197 Hydrochloride	TGF-β Receptor	Cancer
Vactosertib Hydrochloride (EW-7197 Hydrochloride) is a potent, orally active and ATP-competitive activin receptor-like kinase 5 (ALK5) inhibitor with an IC₅₀ of 12.9 nM. Vactosertib Hydrochloride also inhibits ALK2 and ALK4 (IC₅₀ of 17.3 nM) at nanomolar concentrations. Vactosertib Hydrochloride has potently antimetastatic activity and anticancer effect .

HY-111482

SM 16 5 Publications Verification	TGF-β Receptor	Cardiovascular Disease Inflammation/Immunology Cancer
SM 16 is a *ALK5/ALK4* kinase inhibitor with K_is of 10 and 1.5 nM, respectively.

HY-18758

IN-1130 1 Publications Verification	TGF-β Receptor	Inflammation/Immunology Cancer
IN-1130 is a highly selective transforming growth factor-β type I receptor kinase (ALK5) inhibitor with an IC₅₀ of 5.3 nM for ALK5-mediated Smad3 phosphorylation. IN-1130 inhibits ALK5 phosphorylation of casein (IC₅₀=36 nM) and p38α mitogen-activated protein kinase (IC₅₀=4.3 μM). IN-1130 suppresses renal fibrosis in obstructive nephropathy and blocks breast cancer lung metastasis .

HY-78349

A 77-01 2 Publications Verification	TGF-β Receptor	Cancer
A 77-01 is a potent inhibitor of transforming growth factor (TGF)-β type I receptor superfamily activin-like kinase ALK5 with an IC₅₀ of 25 nM .

HY-10431R

SB-431542 (Standard)	Apoptosis TGF-β Receptor Organoid Reference Standards	Cancer
SB-431542 (Standard) is the analytical standard of SB-431542. SB-431542 is a *TGF-β receptor kinase* inhibitor (TRKI)*. SB-431542 has inhibitory activity for ALK4, ALK5* and ALK7 with IC₅₀ values of 1 μM, 0.75 μM and 2 μM, respectively. SB-431542 also inhibits TGF-β-induced transcription, gene expression, apoptosis, and growth suppression. SB-431542 can be used for the research of cancer and signal transduction pathways .

HY-117887

Fidrisertib BLU-782; IPN-60130; ALK2-IN-1	TGF-β Receptor	Cancer
Fidrisertib (BLU-782) is the orally active inhibitor for *activin receptor-like kinase* 2** (ALK2) that inhibits ALK2 ^R206H, *ALK2, ALK1, ALK6, ALK3, ALK4, TGFβR2* and *ALK5* with IC₅₀s of 0.2, 0.6, 3, 24, 45, 65, 67 and 155 nM, respectively .

HY-151289

ALK5-IN-34	TGF-β Receptor TGF-beta/Smad	Cancer
ALK5-IN-34 is an selective orally active activin receptor-like kinase (ALK) inhibitor. ALK5-IN-34 can inhibit the activity of ALK5-IN-34 with an IC₅₀ value of ≤10 nM. ALK5-IN-34 also has inhibitory of tumor growth and can be used for the research of proliferative diseases, such as cancer .

HY-135366

HPN-01	IKK	Inflammation/Immunology
HPN-01 is a potent and selective IKK inhibitor, with pIC₅₀ values of 6.4, 7.0 and <4.8 for IKK-α, IKK-β and IKK-ε, respectively. HPN-01 displays greater 50-fold selectivity over a panel of more than 50 other kinases, including ALK5, CDK-2, EGFR, ErbB2, GSK3β, PLK1, Src, and VEGFR-2 .

HY-10432R

A 83-01 (Standard)	Reference Standards TGF-β Receptor	Cancer
A 83-01 (Standard) is the analytical standard of A 83-01 (HY-10432). This product is intended for research and analytical applications. A 83-01 is a potent inhibitor of TGF-β type I receptor **ALK5 kinase, type I nodal receptor ALK4 and type I nodal receptor ALK7, with IC₅₀s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7**, respectively .

HY-137918

TGF-βRI inhibitor 3	Src TGF-β Receptor Anaplastic lymphoma kinase (ALK)	Others
TGF-βRI inhibitor 3 (Compound 9ac) is a selective TGF-β inhibitor. TGF-βRI inhibitor 3 can effectively inhibit the TGF-β signaling pathway. TGF-βRI inhibitor 3 has IC₅₀ values of 13 μM and 0.63 μM for c-Src kinase and *ALK5* kinase, respectively .

HY-125851

TP-008	TGF-β Receptor	Inflammation/Immunology
TP-008, a chemical probe, is a potent, selective and orally active (Activin-Like Kinase 5) ALK5 inhibitor with pIC₅₀ and pEC₅₀ values of 7.6 and 6.63, respectively. TGFβRI-IN-2 can produce observed cardiac toxicity in vivo at high dose .

HY-118528A

TP0427736 hydrochloride 2 Publications Verification	TGF-β Receptor	Endocrinology
TP0427736 hydrochloride is a potent inhibitor of *ALK5* kinase activity with an IC₅₀ of 2.72 nM and this effect is 300-fold higher than the inhibitory effect on ALK3 (IC₅₀=836 nM). TP0427736 hydrochloride also inhibits Smad2/3 phosphorylation in A549 cells induced by TGF-β1 with an IC₅₀ value of 8.68 nM. TP0427736 hydrochloride can be used for the research of androgenic alopecia (AGA) .

HY-151275

ALK5-IN-28	TGF-β Receptor TGF-beta/Smad	Cancer
ALK5-IN-28 (Compound Ex-05) is a selective ALK-5 inhibitor (IC₅₀ ≤ 10 nM) that inhibits TGF-β-induced SMAD signaling. ALK5-IN-28 has the potential to inhibit tumor growth in vivo. ALK5-IN-28 can be used in the research of proliferative diseases such as cancer .

HY-13012R

RepSox (Standard) E-616452 (Standard); SJN 2511 (Standard)	Organoid TGF-β Receptor Reference Standards	Metabolic Disease
RepSox (Standard) is the analytical standard of RepSox. This product is intended for research and analytical applications. RepSox (E-616452) is a potent and selective transforming growth factor-beta receptor I/activin like kinase 5 (TGF-β-RI/ALK5) inhibitor. RepSox inhibits ALK5 autophosphorylation with an IC50 value of 4 nM. RepSox can be used for the research of obesity and associated metabolic diseases such as type 2 diabetes .

HY-151277

ALK5-IN-29	Anaplastic lymphoma kinase (ALK)	Cancer
ALK5-IN-29 is an selective activin receptor-like kinase (ALK) inhibitor. ALK5-IN-29 can inhibit the activity of ALK5 with an IC₅₀ value of ≤10 nM. ALK5-IN-29 also has inhibitory of tumor growth and can be used for the research of proliferative diseases, such as cancer .

HY-151272

ALK5-IN-26	Anaplastic lymphoma kinase (ALK)	Cancer
ALK5-IN-26 (EX-22) is an *ALK* (Activin receptor-like kinase) inhibitor. ALK5-IN-26 inhibits ALK5 with an IC₅₀ value ≤10 nM. ALK5-IN-26 can be used for the research of cancer .

HY-151233

ALK5-IN-10	TGF-β Receptor	Cancer
ALK5-IN-10 (Compound 5d) is a TGF-β type I receptor kinase *ALK5* inhibitor, with IC₅₀s of 0.007 and 1.98 μM for ALK5 and p38α, respectively. ALK5-IN-10 can be used for the research of cancer .

HY-162902

ALK5-IN-82	TGF-β Receptor	Cardiovascular Disease
ALK5-IN-82 is a potent and selective inhibitor against activin receptor-like kinase 5 (ALK5) with an IC₅₀ value of 9.1 nM. ALK5-IN-82 inhibits the protein expression of α-smooth muscle actin (α-SMA), collagen I and tissue inhibitor of metalloproteinase 1 (TIMP-1)/matrix metalloproteinase 13 (MMP-13) in transforming growth factor-β-induced human umbilical vein endothelial cells. ALK5-IN-82 is promising for research of cardiac fibrosis .

HY-W707119

RepSox hydrochloride E-616452 hydrochloride; SJN 2511 hydrochloride	TGF-beta/Smad Anaplastic lymphoma kinase (ALK)	Metabolic Disease
RepSox hydrochloride is a potent and selective inhibitor of transforming growth factor-β receptor I/activin-like kinase 5 (TGF-β-RI/ALK5). RepSox hydrochloride inhibits ALK5 autophosphorylation with an IC50 value of 4 nM. RepSox hydrochloride can be used in the study of obesity and related metabolic diseases such as type 2 diabetes.

HY-18758R

IN-1130 (Standard)	TGF-β Receptor	Inflammation/Immunology Cancer
IN-1130 (Standard) is the analytical standard of IN-1130. This product is intended for research and analytical applications. IN-1130 is a highly selective transforming growth factor-β type I receptor kinase (ALK5) inhibitor with an IC50 of 5.3 nM for ALK5-mediated Smad3 phosphorylation. IN-1130 inhibits ALK5 phosphorylation of casein (IC50=36 nM) and p38α mitogen-activated protein kinase (IC50=4.3 μM). IN-1130 suppresses renal fibrosis in obstructive nephropathy and blocks breast cancer lung metastasis .

HY-149403

J-1048	Anaplastic lymphoma kinase (ALK)	Others
J-1048 is an activin receptor-like kinase 5 *(ALK5)* inhibitor. J-1048 can inhibit TAA-induced liver fibrosis in mice by explicitly blocking the TGF-β/Smad signaling pathway .

HY-163429

J-1149	TGF-β Receptor p38 MAPK	Inflammation/Immunology Cancer
J-1149 is a potent *ALK5* inhibitor, with an IC₅₀ value of 0.017 μM. J-1149 also shows weak p38α MAP kinase inhibitory activity, with an IC₅₀ value of 0.435 μM. J-1149 can be used for liver fibrosis research .

HY-183441

ALK5 ligand-1	Ligands for Target Protein for PROTAC Anaplastic lymphoma kinase (ALK)	Inflammation/Immunology
ALK5 ligand-1 (a31's ALK5 ligand) is a ligand of Anaplastic lymphoma kinase *ALK5* with higher selectivity for ALK5 than for ALK4. ALK5 ligand-1 can be used to synthesize PROTAC degraders targeting ALK5. ALK5 PROTACs induce *ALK5* degradation dependent on the ubiquitin-proteasome system and exert antifibrotic activity. ALK5 ligand-1 can be used in studies of pulmonary fibrosis .

HY-13012S

RepSox-d5 E-616452-d₅; SJN 2511-d₅	Isotope-Labeled Compounds TGF-β Receptor	Metabolic Disease
RepSox-d₅ (E-616452-d₅) is the deuterium labeled RepSox (HY-13012). RepSox (E-616452) is a potent and selective transforming growth factor-beta receptor I/activin like kinase 5 (TGF-β-RI/ALK5) inhibitor. RepSox inhibits ALK5 autophosphorylation with an IC₅₀ value of 4 nM. RepSox can be used for the research of obesity and associated metabolic diseases such as type 2 diabetes .

HY-163507

ALK5-IN-79	Anaplastic lymphoma kinase (ALK)	Cancer
ALK5-IN-79 (compound 57) is an ALK inhibitor with anticancer activity, by blocking TGF-β1/SMAD signaling pathway. ALK5-IN-79 attenuates the production of extracellular matrix (ECM) and deposition of collagen. ALK5-IN-79 exhibits adequate pharmacokinetic (PK) properties and good in vivo tolerance.

HY-185430

HM-279	TGF-β Receptor	Inflammation/Immunology Cancer
HM-279 is a potent and orally active *ALK5* inhibitor with an IC₅₀ of 4.7 nM. HM-279 shows cross-reactivity with *ALK7* (IC₅₀ = 6.8 nM), but HM-279 has fair to good selectivity against other TGF-β receptor family kinases, with 4.5-693-fold selectivity. HM-279 demonstrates antitumor activity in vivo through CD8 ⁺ T cell immunity. HM-279 can be used for the research of colon cancer .

HY-181139

ALK5-IN-86	Anaplastic lymphoma kinase (ALK)	Metabolic Disease
ALK5-IN-86 (Compound 22f) is a selective ALK5 inhibitor with an IC₅₀ of 0.267 μM. ALK5-IN-86 forms hydrogen bonds with key amino acid residues in the active site of ALK5. ALK5-IN-86 is applicable to the research of diseases such as liver fibrosis .

HY-182547

LY580276	Anaplastic lymphoma kinase (ALK)	Cancer
LY580276 is an ATP-competitive ALK5 inhibitor with an IC₅₀ of 175 nM. LY580276 inhibits transforming growth factor-β-induced epithelial-mesenchymal transition. LY580276 can be used for cancer research .

HY-179400

LDN-193688	Anaplastic lymphoma kinase (ALK) TGF-beta/Smad	Others
LDN-193688 (Compound 26) is a ALK2 inhibitor, with IC₅₀ values of 104, 18, 235, 1530, and 1080 nM against ALK1, ALK2, ALK3, ALK4, and ALK5, respectively. LDN-193688 inhibits bone morphogenetic protein 4 (BMP4)-induced phosphorylation of SMAD1/5/8, with an IC₅₀ of 2.6 μM .

HY-183718

M4K3250	PROTACs Anaplastic lymphoma kinase (ALK)	Neurological Disease Cancer
M4K3250 is a selective ALK2 PROTAC degrader with a pDC₅₀ of 7.9. M4K3250 induces the formation of a ternary complex between ALK2 and the E3 ubiquitin ligase CRBN, thereby causing ALK2 degradation and inhibiting ALK2 activity. M4K3250 exhibits cytotoxicity in glioblastoma cells. M4K3250 can be used in studies related to glioblastoma .

Cat. No.	Product Name	Chemical Structure

HY-13012S

RepSox-d5
RepSox-d₅ (E-616452-d₅) is the deuterium labeled RepSox (HY-13012). RepSox (E-616452) is a potent and selective transforming growth factor-beta receptor I/activin like kinase 5 (TGF-β-RI/ALK5) inhibitor. RepSox inhibits ALK5 autophosphorylation with an IC₅₀ value of 4 nM. RepSox can be used for the research of obesity and associated metabolic diseases such as type 2 diabetes .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: